Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN) announced its participation in the Oppenheimer 32nd Annual Global Healthcare Conference on March 16, 2022, at 11:20 am ET. The presentation will be accessible via live webcast on Compugen's Investor Relations page, with a replay available afterward. Compugen specializes in cancer immunotherapy and has developed key products such as COM701 and COM902, both in Phase 1 clinical trials. The company is headquartered in Israel and has a strong pipeline of immuno-oncology programs targeting various immune resistance mechanisms.

HOLON, Israel, March 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the Oppenheimer 32^nd Annual Global Healthcare Conference (virtual), on Wednesday, March 16, 2022 at 11:20 am ET.

A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 clinical trials as a single agent and in dual, and triple combinations; COM902, a potential best-in-class monoclonal antibody targeting TIGIT for the treatment of solid and hematological tumors, is undergoing Phase 1 clinical trials as a single agent and in dual combination with COM701. Partnered programs include bapotulimab, an antibody targeting ILDR2 in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and AZD2939, an anti TIGIT/PD-1 bispecific antibody developed by AstraZeneca with a TIGIT component that is derived from the COM902 program pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase 1/2. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Investor Relations contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications Compugen Ltd.
Email: ir@cgen.com
Tel.: +1 (628) 241-0071

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-oppenheimer-32nd-annual-global-healthcare-conference-301498952.html

SOURCE Compugen Ltd.

FAQ

When will Compugen present at the Oppenheimer Healthcare Conference?

Compugen will present at the Oppenheimer 32nd Annual Global Healthcare Conference on March 16, 2022, at 11:20 am ET.

How can I watch Compugen's presentation at the conference?

The presentation will be available via live webcast on Compugen's Investor Relations section of their website.

What are Compugen’s main product candidates?

Compugen's main product candidates include COM701 and COM902, both undergoing Phase 1 clinical trials.

What is the focus of Compugen's research?

Compugen focuses on cancer immunotherapy and utilizes predictive computational discovery for new drug targets.

Where is Compugen headquartered?

Compugen is headquartered in Israel, with additional offices in South San Francisco, CA.